Pharma’s Troubled Future

Last month Gilead Sciences announced that its drug Sovaldi brought in a mammoth $3.5 billion in sales. The medicine completely cures people of hepatitis C but comes with a hefty price tag: $84,000, or roughly $1,000 per pill. This high-profile case brings up many of the challenging issues facing the pharmaceutical (including, for the purposes of this ar…